Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
Breast Cancer Research and Treatment
|
April 28, 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32
Ana Elisa Lohmann, Mira F Liebman, William Brien, et al.
Annals of Surgical Oncology
|
November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of the National Cancer Institute
|
March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S Kim, Nan Song, Patrick G Gavin, et al.
Journal of the National Cancer Institute
|
July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)
Yara Abdou, Jess Hoag, William E Barlow, et al.
Journal of the National Cancer Institute
|
February 2, 2021
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32
Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Charles E Geyer, Joanne L Blum, Greg Yothers, et al.
NPJ Breast Cancer
|
November 12, 2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Otto Metzger-Filho, Katharine Collier, Sarah Asad, et al.
The Lancet. Oncology
|
December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Stephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer
Mariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
Breast Cancer Research and Treatment
|
April 28, 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32
Ana Elisa Lohmann, Mira F Liebman, William Brien, et al.
Annals of Surgical Oncology
|
November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of the National Cancer Institute
|
March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S Kim, Nan Song, Patrick G Gavin, et al.
Journal of the National Cancer Institute
|
July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)
Yara Abdou, Jess Hoag, William E Barlow, et al.
Journal of the National Cancer Institute
|
February 2, 2021
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32
Isabel Pimentel, Bingshu E Chen, Ana Elisa Lohmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Charles E Geyer, Joanne L Blum, Greg Yothers, et al.
NPJ Breast Cancer
|
November 12, 2021
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Otto Metzger-Filho, Katharine Collier, Sarah Asad, et al.
The Lancet. Oncology
|
December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Stephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2024
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer
Mariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Page
of 9